PriceTargets.com logo

Decoy Therapeutics - DCOY Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $2.50
  • Forecasted Upside: 247.27%
  • Number of Analysts: 2
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.72 As of 02/2/2026 05:00 PM ET
▼ -0.051 (-6.62%)

This chart shows the closing price for DCOY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Decoy Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DCOY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DCOY

Analyst Price Target is $2.50
▲ +247.27% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Decoy Therapeutics in the last 3 months. The average price target is $2.50, with a high forecast of $2.50 and a low forecast of $2.50. The average price target represents a 247.27% upside from the last price of $0.72.

This chart shows the closing price for DCOY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 2 investment analysts is to hold stock in Decoy Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/11/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/8/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/6/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/3/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/2/2026

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/23/2026LADENBURG THALM/SH SHInitiated CoverageBuy$2.50
1/22/2026Weiss RatingsInitiated CoverageSell (E)
(Data available from 2/2/2021 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/3/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/2/2026

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.

Decoy Therapeutics

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
Read More

Today's Range

Now: $0.72
Low: $0.67
High: $0.78

50 Day Range

MA: N/A

52 Week Range

Now: $0.72
Low: $0.51
High: $35.70

Volume

359,308 shs

Average Volume

6,362,863 shs

Market Capitalization

$4.59 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.39

Frequently Asked Questions

What sell-side analysts currently cover shares of Decoy Therapeutics?

The following sell-side analysts have issued reports on Decoy Therapeutics in the last twelve months: LADENBURG THALM/SH SH, and Weiss Ratings.
View the latest analyst ratings for DCOY.

What is the current price target for Decoy Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Decoy Therapeutics in the last year. Their average twelve-month price target is $2.50, suggesting a possible upside of 247.3%. LADENBURG THALM/SH SH has the highest price target set, predicting DCOY will reach $2.50 in the next twelve months. LADENBURG THALM/SH SH has the lowest price target set, forecasting a price of $2.50 for Decoy Therapeutics in the next year.
View the latest price targets for DCOY.

What is the current consensus analyst rating for Decoy Therapeutics?

Decoy Therapeutics currently has 1 sell rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in DCOY, but not buy more shares or sell existing shares.
View the latest ratings for DCOY.

What other companies compete with Decoy Therapeutics?

Other companies that are similar to Decoy Therapeutics include Neuphoria Therapeutics, Klotho Neurosciences, Athira Pharma, Synergy CHC and BioAtla. Learn More about companies similar to Decoy Therapeutics.

How do I contact Decoy Therapeutics' investor relations team?

Decoy Therapeutics' physical mailing address is 2450 HOLCOMBE BLVD, SUITE J-608, HOUSTON, TX, 77021. The company's listed phone number is (346) 772-0346 and its investor relations email address is [email protected]. The official website for Decoy Therapeutics is salariuspharma.com. Learn More about contacing Decoy Therapeutics investor relations.